Ruben A. Mesa, Uma Yasothan, Peter Kirkpatrick

Research output: Contribution to journalReview article

102 Scopus citations


In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.

Original languageEnglish (US)
Pages (from-to)103-104
Number of pages2
JournalNature Reviews Drug Discovery
Issue number2
StatePublished - Feb 1 2012

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Ruxolitinib'. Together they form a unique fingerprint.

  • Cite this

    Mesa, R. A., Yasothan, U., & Kirkpatrick, P. (2012). Ruxolitinib. Nature Reviews Drug Discovery, 11(2), 103-104.